These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17206389)

  • 1. Lipid-altering therapies and the progression of atherosclerotic disease.
    Wierzbicki AS
    Cardiovasc Intervent Radiol; 2007; 30(2):155-60. PubMed ID: 17206389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence to support aggressive management of high-density lipoprotein cholesterol: implications of recent imaging trials.
    Taylor AJ
    Am J Cardiol; 2008 Apr; 101(8A):36B-43B. PubMed ID: 18375240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atherosclerotic disease regression with statins: studies using vascular markers.
    Grobbee DE; Bots ML
    Int J Cardiol; 2004 Sep; 96(3):447-59. PubMed ID: 15301899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of lipid modification on progression of coronary calcification.
    McCullough PA
    J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S115-9. PubMed ID: 16251246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R; Mahajan M; Singh B; Bal BS; Kant R
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-density lipoprotein metabolism: potential therapeutic targets.
    Davidson MH; Toth PP
    Am J Cardiol; 2007 Dec; 100(11 A):n32-40. PubMed ID: 18047851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?
    Wierzbicki AS
    Curr Med Res Opin; 2005 Feb; 21(2):299-306. PubMed ID: 15802001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Who needs to care about small, dense low-density lipoproteins?
    Rizzo M; Berneis K
    Int J Clin Pract; 2007 Nov; 61(11):1949-56. PubMed ID: 17935554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins may be beneficial for patients with slow coronary flow syndrome due to its anti-inflammatory property.
    Li JJ; Zheng X; Li J
    Med Hypotheses; 2007; 69(2):333-7. PubMed ID: 17215087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P
    Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of statins in reversing atherosclerosis: what the latest regression studies show.
    Grines CL
    J Interv Cardiol; 2006 Feb; 19(1):3-9. PubMed ID: 16483333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors.
    Davidson MH
    Am J Manag Care; 2007 Dec; 13 Suppl 10():S260-9. PubMed ID: 18095776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aggressive statin therapy reduces the progression of atherosclerosis-- DMW15/2005].
    Taut V
    Dtsch Med Wochenschr; 2006 Mar; 131(9):460; author reply 460. PubMed ID: 16493575
    [No Abstract]   [Full Text] [Related]  

  • 17. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
    Mason RP; Walter MF; Day CA; Jacob RF
    Am J Cardiol; 2005 Sep; 96(5A):11F-23F. PubMed ID: 16126019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry.
    Gitt AK; Juenger C; Jannowitz C; Karmann B; Senges J; Bestehorn K
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):438-44. PubMed ID: 19369876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
    Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL
    Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for aggressive lipid lowering: evidence from clinical trials.
    Farmer JA
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):305-9. PubMed ID: 15151477
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.